HK1214261A1 - 脫氧吉瑞霉素和d-阿拉伯膠素醇類似物及使用方法 - Google Patents

脫氧吉瑞霉素和d-阿拉伯膠素醇類似物及使用方法 Download PDF

Info

Publication number
HK1214261A1
HK1214261A1 HK16102398.6A HK16102398A HK1214261A1 HK 1214261 A1 HK1214261 A1 HK 1214261A1 HK 16102398 A HK16102398 A HK 16102398A HK 1214261 A1 HK1214261 A1 HK 1214261A1
Authority
HK
Hong Kong
Prior art keywords
substituted
compound
unsubstituted
formula
alkyl
Prior art date
Application number
HK16102398.6A
Other languages
English (en)
Chinese (zh)
Inventor
D. Butters Terry
A. Dwek Raymond
W. J. Fleet George
Original Assignee
United Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corporation filed Critical United Therapeutics Corporation
Publication of HK1214261A1 publication Critical patent/HK1214261A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16102398.6A 2006-05-24 2016-03-02 脫氧吉瑞霉素和d-阿拉伯膠素醇類似物及使用方法 HK1214261A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80277606P 2006-05-24 2006-05-24
US60/802776 2006-05-24

Publications (1)

Publication Number Publication Date
HK1214261A1 true HK1214261A1 (zh) 2016-07-22

Family

ID=38779322

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102398.6A HK1214261A1 (zh) 2006-05-24 2016-03-02 脫氧吉瑞霉素和d-阿拉伯膠素醇類似物及使用方法

Country Status (8)

Country Link
US (1) US8975280B2 (enExample)
EP (1) EP2023927B1 (enExample)
JP (2) JP5241709B2 (enExample)
CN (2) CN104876855A (enExample)
CA (1) CA2652958C (enExample)
ES (1) ES2537572T3 (enExample)
HK (1) HK1214261A1 (enExample)
WO (1) WO2007140184A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138351A1 (en) * 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
US20090252785A1 (en) * 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
JP5600329B2 (ja) * 2009-02-23 2014-10-01 ユナイテッド セラピューティクス コーポレーション イミノ糖およびウイルス性疾患を治療する方法
KR101787434B1 (ko) 2009-02-24 2017-11-15 유나이티드 세러퓨틱스 코오포레이션 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법
CN102427804A (zh) * 2009-03-27 2012-04-25 牛津大学之校长及学者 降低胆固醇水平的脂质体
WO2010111711A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
JP5634510B2 (ja) * 2009-06-12 2014-12-03 ユナイテッド セラピューティクス コーポレイション イミノ糖ならびにブニヤウイルスおよびトガウイルス疾患を治療する方法
KR101497194B1 (ko) * 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
JP5752689B2 (ja) * 2009-09-04 2015-07-22 ユナイテッド セラピューティクス コーポレイション フィロウイルス疾患を治療するイミノ糖および方法
KR101459530B1 (ko) * 2009-09-04 2014-11-07 유나이티드 세러퓨틱스 코오포레이션 폭스바이러스 감염의 치료 방법
CN104703597A (zh) 2012-06-06 2015-06-10 尤尼特尔滤过性微生物学有限责任公司 新型亚氨基糖及它们的应用
CN105246478A (zh) 2013-03-15 2016-01-13 优尼特尔病毒学公司 抗菌化合物
HK1221871A1 (zh) * 2013-05-02 2017-06-16 The Chancellor, Masters And Scholars Of The University Of Oxford 使用亚氨基糖进行的糖脂抑制
MX2016003323A (es) 2013-09-16 2016-08-12 Emergent Virology Llc Derivados de dosoxinojirimicina y sus metodos de uso.
CA2966893C (en) 2014-11-05 2023-10-24 Emergent Virology Llc Iminosugars
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS54106477A (en) 1978-02-03 1979-08-21 Nippon Shinyaku Co Ltd Moranoline derivative
JPS5943947B2 (ja) * 1978-05-03 1984-10-25 日本新薬株式会社 Ｎ−置換モラノリン誘導体
JPS5943949B2 (ja) 1978-09-29 1984-10-25 日本新薬株式会社 モラノリンのｎ−置換誘導体
JPS5943948B2 (ja) * 1978-07-06 1984-10-25 日本新薬株式会社 置換モラノリン誘導体
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
DE3007078A1 (de) 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
JPS62155291A (ja) 1985-12-20 1987-07-10 バイエル・アクチエンゲゼルシヤフト ３−アミノ−４，５−ジヒドロキシピペリジン類、それらの製造方法及びそれらの使用
DE3620645A1 (de) 1985-12-20 1987-07-02 Bayer Ag 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
JPH0643306B2 (ja) * 1988-02-12 1994-06-08 明治製菓株式会社 癌細胞転移抑制剤
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
EP0350012A3 (en) 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
EP0367747B1 (en) * 1988-11-03 1996-03-13 G.D. Searle & Co. Dideoxy-L-arabinitol derivatives as antiviral compounds
JPH0675510B2 (ja) 1989-02-13 1994-09-28 日本新薬株式会社 モラノリン誘導体の製法
US5256788A (en) 1989-02-13 1993-10-26 Nippon Shinyaku Co. Ltd. Moranoline derivatives and their production and the use of moranoline and its derivatives as a stabilizing agent for enzymes
US5051401A (en) * 1989-04-07 1991-09-24 University Of South Alabama Inhibition of mineral deposition by phosphorylated and related polyanionic peptides
DE4009561A1 (de) 1990-03-24 1991-09-26 Bayer Ag Neue desoxynojirimycinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
CA2086413A1 (en) 1990-06-29 1991-12-30 Yohji Ezure Piperidine derivatives
US5290948A (en) 1990-09-17 1994-03-01 Mcneilab, Inc. Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
DE69421828T2 (de) 1994-01-13 2000-04-20 G.D. Searle & Co. Verwendung von 1,5-dideoxy-1,5-imino-d-glucitol n-alkylderivaten zur behandlung von hepatitis b infektionen
WO1995022975A1 (en) 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
DK1030839T3 (da) 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
US6809083B1 (en) * 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
EP1261339A1 (en) 2000-02-14 2002-12-04 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
ES2271548T3 (es) * 2002-03-13 2007-04-16 Unither Pharmaceuticals, Inc. Enfoque no hormonal de anticoncepcion masculina.
AU2003248960B2 (en) * 2002-07-17 2009-06-25 Idorsia Pharmaceuticals Ltd Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives

Also Published As

Publication number Publication date
WO2007140184A2 (en) 2007-12-06
WO2007140184A3 (en) 2008-11-27
EP2023927A4 (en) 2013-04-10
US8975280B2 (en) 2015-03-10
US20070275998A1 (en) 2007-11-29
CN104876855A (zh) 2015-09-02
EP2023927B1 (en) 2015-02-25
ES2537572T3 (es) 2015-06-09
JP5241709B2 (ja) 2013-07-17
EP2023927A2 (en) 2009-02-18
CA2652958A1 (en) 2007-12-06
JP2013129662A (ja) 2013-07-04
CN101489554A (zh) 2009-07-22
JP2009538336A (ja) 2009-11-05
CA2652958C (en) 2015-11-17

Similar Documents

Publication Publication Date Title
CN104876855A (zh) 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法
US5863903A (en) Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
EP0749423B1 (en) Piperidines and pyrrolidines
Aguilar-Moncayo et al. Bicyclic (galacto) nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase
WO1998006697A1 (en) Ether muscarinic antagonists
López et al. Glycosidase inhibitors: versatile tools in glycobiology
EP1903034A1 (en) Iminosugar glycoconjugates
US6020344A (en) Enzyme inhibitors and methods of use
Kooij et al. Glycosidase inhibition by novel guanidinium and urea iminosugar derivatives
EP1885696A1 (en) Glycosidase-inhibiting iminosugars
Steiner et al. 1-Deoxygalactonojirimycin-lysine hybrids as potent D-galactosidase inhibitors
Ashmus et al. Rational design of cell active C2-modified DGJ analogues for the inhibition of human α-galactosidase A (GALA)
Lundt et al. Fluorescently tagged iminoalditol glycosidase inhibitors as novel biological probes and diagnostics
Blériot et al. Sugar-derived amidines and congeners: structures, glycosidase inhibition and applications
Fröhlich et al. 1-Deoxy-d-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines
Matassini et al. The double reductive amination approach to the synthesis of polyhydroxypiperidines
Markad et al. Polyhydroxylated homoazepanes and 1-deoxy-homonojirimycin analogues: Synthesis and glycosidase inhibition study
US20210061761A1 (en) Modulators of complex i
US20140296288A1 (en) Imino-sugar c-glycosides, preparation and use thereof
Iftikhar et al. An Overview of Debenzylation Methods to Obtain 1-Deoxynojirimycin (DNJ)
EP3009444B1 (en) Alpha-oxoacyl amino-caprolactam derivative
RU2762605C1 (ru) Способ получения (2R,3R,4R,5S)-1-бутил-2-(гидроксиметил)пиперидин-3,4,5-триола
Clemente Synthesis of alkylated azasugars and their therapeutic potential against lysosomal storage and neurological disorders: the Gaucher-Parkinson case
EP3088389A1 (en) 4-epi-isofagomine derivatives
Martínez-Castro et al. Intramolecular cyclization of alkoxyaminosugars: access to novel glycosidase inhibitor families